Surfix is leading innovation in the medical technology field with its advanced Photonic Diagnostics Platform. This breakthrough platform combines six cutting-edge technologies, offering a multimodal point-of-care solution with laboratory-grade precision. The platform consists of a versatile readout instrument and cartridge, enabling both immuno- and molecular assays, and can handle challenging samples like liquid biopsies with ultra-low biomarker concentrations.

This unique capability opens the door to previously unaddressed biomarkers, offering unprecedented clinical insights into a wide range of disease states, including sepsis, cancer, cardiac disease, and infectious diseases. Surfix is actively seeking strategic partners to co-develop assays for these point-of-care applications.